RadioMedix, Inc. Our focus lies in commercializing radiopharmaceuticals for PET imaging as well as targeted alpha and beta-emitter therapy. With a commitment to providing comprehensive solutions, we cover the entire value chain from drug discovery to sponsoring and conducting clinical trials, all the way to scale up manufacturing.

As a company compliant with 21 CFR Parts 210, 211, and 212, we ensure the highest quality standards in our operations. Our Molecular Core Facility supports the synthesis and pre-clinical evaluation of our drugs and contract projects, while our cGMP Suite manufactures doses for Phase I-III clinical trials. Moreover, our state-of-the-art commercial manufacturing site, The Spica Center, is equipped for scaled-up and commercial-grade production of radiolabeled drugs and isotopes.

At RadioMedix, our mission is to enhance the lives of patients by providing innovative radiotheranostics and accelerating discoveries in nuclear medicine. Led by our founder and chairman of the board, Ebrahim S. Delpassand, MD, a board-certified nuclear medicine physician and former deputy chair and chief of clinical nuclear medicine at MD.

Anderson Cancer Center, our management team is dedicated to driving advancements in the field. Join us in our efforts to revolutionize cancer diagnosis and treatment